158 related articles for article (PubMed ID: 36882838)
1. Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
Hathaway CA; Rice MS; Collins LC; Chen D; Frank DA; Walker S; Clevenger CV; Tamimi RM; Tworoger SS; Hankinson SE
Breast Cancer Res; 2023 Mar; 25(1):24. PubMed ID: 36882838
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland.
Nyante SJ; Faupel-Badger JM; Sherman ME; Pfeiffer RM; Gaudet MM; Falk RT; Andaya AA; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Chanock S; Garcia-Closas M; Figueroa JD
Breast Cancer Res; 2011 Apr; 13(2):R42. PubMed ID: 21470416
[TBL] [Abstract][Full Text] [Related]
3. Prolactin receptor-mediated activation of pSTAT5 in the pregnant mouse brain.
Gustafson P; Ladyman SR; McFadden S; Larsen C; Khant Aung Z; Brown RSE; Bunn SJ; Grattan DR
J Neuroendocrinol; 2020 Nov; 32(11):e12901. PubMed ID: 33000513
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.
Lee SA; Haiman CA; Burtt NP; Pooler LC; Cheng I; Kolonel LN; Pike MC; Altshuler D; Hirschhorn JN; Henderson BE; Stram DO
BMC Med Genet; 2007 Dec; 8():72. PubMed ID: 18053149
[TBL] [Abstract][Full Text] [Related]
5. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
6. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.
Tworoger SS; Sluss P; Hankinson SE
Cancer Res; 2006 Feb; 66(4):2476-82. PubMed ID: 16489055
[TBL] [Abstract][Full Text] [Related]
7. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling.
García-Martínez JM; Calcabrini A; González L; Martín-Forero E; Agulló-Ortuño MT; Simon V; Watkin H; Anderson SM; Roche S; Martín-Pérez J
Cell Signal; 2010 Mar; 22(3):415-26. PubMed ID: 19892015
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
[TBL] [Abstract][Full Text] [Related]
9. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women.
Eliassen AH; Tworoger SS; Hankinson SE
Int J Cancer; 2007 Apr; 120(7):1536-41. PubMed ID: 17211859
[TBL] [Abstract][Full Text] [Related]
10. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
11. Increased STAT5 signaling in the ring dove brain in response to prolactin administration and spontaneous elevations in prolactin during the breeding cycle.
Buntin JD; Buntin L
Gen Comp Endocrinol; 2014 May; 200():1-9. PubMed ID: 24530808
[TBL] [Abstract][Full Text] [Related]
12. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
13. Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways.
Ali S; Ali S
J Biol Chem; 1998 Mar; 273(13):7709-16. PubMed ID: 9516478
[TBL] [Abstract][Full Text] [Related]
14. Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.
Haglund F; Lu M; Vukojević V; Nilsson IL; Andreasson A; Džabić M; Bränström R; Höög A; Juhlin CC; Larsson C
PLoS One; 2012; 7(5):e36448. PubMed ID: 22606260
[TBL] [Abstract][Full Text] [Related]
15. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.
Faupel-Badger JM; Sherman ME; Garcia-Closas M; Gaudet MM; Falk RT; Andaya A; Pfeiffer RM; Yang XR; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Figueroa JD
Br J Cancer; 2010 Sep; 103(7):1097-102. PubMed ID: 20736944
[TBL] [Abstract][Full Text] [Related]
16. Prolactin regulation of the HPA axis is not mediated by a direct action upon CRH neurons: evidence from the rat and mouse.
Gustafson P; Kokay I; Sapsford T; Bunn S; Grattan D
Brain Struct Funct; 2017 Sep; 222(7):3191-3204. PubMed ID: 28337596
[TBL] [Abstract][Full Text] [Related]
17. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract][Full Text] [Related]
18. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
19. Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies.
Rice MS; Tworoger SS; Bertrand KA; Hankinson SE; Rosner BA; Feeney YB; Clevenger CV; Tamimi RM
Breast Cancer Res Treat; 2015 Jan; 149(1):245-53. PubMed ID: 25503962
[TBL] [Abstract][Full Text] [Related]
20. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
